A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

N/ARecruitingNCT07200206

Sanofi3,000 enrolled

Overview

This study is conducted as part of the local risk management plan to collect and understand the following information about the surveillance drug under the real-world clinical practice settings. To evaluate the safety of Beyfortus in Korean children who received Beyfortus under the real-world clinical practice settings per the approved indication. The investigator will decide whether to enroll participants if they determine that administering Beyfortus according to current practice can provide clinical benefits in terms of safety and efficacy Participants will be followed-up for 180 days after Beyfortus administration.

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

Respiratory Syncytial Virus

Interventions

NirsevimabBIOLOGICAL

Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Children up to 24 months of age who received Beyfortus according to the approved indications. * Informed consent signed by the parents / legally accepted representatives (LARs) of the participant. Exclusion Criteria: * Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device or a medical procedure. * Any contraindications according to the approved local product label of Beyfortus.